Science | Nature | Cell | View More
Natural Products
Capillarisin
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Capillarisin
Price:
CAS No.: 56365-38-9
Catalog No.: CFN90317
Molecular Formula: C16H12O7
Molecular Weight: 316.26 g/mol
Purity: >=98%
Type of Compound: Flavonoids
Physical Desc.: Powder
Source: The herbs of Artemisia capillaris Thunb.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download: COA    MSDS    SDF    Manual
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / Inquiry
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Texas A&M University (USA)
  • Instituto de Investigaciones Ag... (Chile)
  • Melbourne University (Australia)
  • University of the Basque Country (Spain)
  • University of Hawaii Cancer Center (USA)
  • Korea Institute of Oriental Med... (Korea)
  • Guangzhou Institutes of Biomedi... (China)
  • Shanghai Institute of Biochemis... (China)
  • Sanford Burnham Prebys Medical ... (USA)
  • Osmania University (India)
  • Sant Gadge Baba Amravati Univer... (India)
  • More...
Package
Featured Products
Robinin

Catalog No: CFN98375
CAS No: 301-19-9
Price: $318/5mg
Daidzein

Catalog No: CFN98774
CAS No: 486-66-8
Price: $30/20mg
Oroxylin A

Catalog No: CFN98540
CAS No: 480-11-5
Price: $80/20mg
Isorhamnetin-3-O-beta-D-Glucoside

Catalog No: CFN99757
CAS No: 5041-82-7
Price: $218/10mg
Soyasapogenol D

Catalog No: CFN91069
CAS No: 65892-76-4
Price: $463/5mg
trans-4-Hydroxycinnamic acid

Catalog No: CFN98794
CAS No: 501-98-4
Price: $30/20mg
Ganoderic acid H

Catalog No: CFN92056
CAS No: 98665-19-1
Price: $318/10mg
Cyclo(Tyr-Pro)

Catalog No: CFN90276
CAS No: 5654-84-2
Price: $238/10mg
Calenduloside E

Catalog No: CFN91169
CAS No: 26020-14-4
Price: $268/10mg
Lonicerin

Catalog No: CFN95055
CAS No: 25694-72-8
Price: $168/10mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Capillarisin is a novel blocker of STAT3 activation and thus may have a potential in negative regulation of growth, metastasis, and chemoresistance of tumor cells, it inhibits cancer cell growth of osteosarcoma cells by inducing apoptosis accompanied with G0/G1-phase cell cycle arrest and loss in mitochondrial membrane potential.Capillarisin has anti-inflammatory activity, can inhibit LPS-induced inflammation by blocking TLR4-mediated NF-κB and MAPKs activation in BV2 microglia. Capillarisin possesses promising anti-hyperalgesic and anti-allodynic effects through the inhibition of various inflammatory pain signaling.
Targets: TLR | NF-kB | MAPK | STAT | TNF-α | IL Receptor | NO | PGE | AP-1 | ERK | NOS | COX | MMP(e.g.TIMP) | VEGFR | JNK | Bcl-2/Bax
In vitro:
Neurochem Res. 2015 Jun;40(6):1095-101.
Capillarisin Suppresses Lipopolysaccharide-Induced Inflammatory Mediators in BV2 Microglial Cells by Suppressing TLR4-Mediated NF-κB and MAPKs Signaling Pathway.[Pubmed: 25894679]
Capillarisin, one of the major bioactive compounds derived from Artemisia capillaries Thunb, has been reported to have extensive pharmacological properties, such as ant-inflammatory and anti-nociceptive activities. However, the molecular mechanisms responsible for the anti-inflammatory activity of Capillarisin have not been elucidated in microglia.
METHODS AND RESULTS:
In the present study, we investigated the anti-inflammatory effects and molecular mechanisms of Capillarisin on LPS-stimulated BV2 microglial cells. The effects of Capillarisin on inflammatory mediators TNF-α, IL-6, IL-1β, NO and PGE2 were detected. The effects of Capillarisin on NF-κB and MAPK activation were detected by western blotting. The results showed that Capillarisin suppressed LPS-induced TNF-α, IL-6, IL-1β, NO and PGE2 production in a dose-dependent manner. Capillarisin also inhibited LPS-induced TLR4 expression, NF-κB and MAPKs activation in BV2 microglia.
CONCLUSIONS:
In conclusion, Capillarisin inhibited LPS-induced inflammation by blocking TLR4-mediated NF-κB and MAPKs activation in BV2 microglia.
Immunopharmacol Immunotoxicol. 2013 Feb;35(1):34-42.
Capillarisin inhibits iNOS, COX-2 expression, and proinflammatory cytokines in LPS-induced RAW 264.7 macrophages via the suppression of ERK, JNK, and NF-κB activation.[Pubmed: 23131135]
The aerial parts of Artemisia capillaris (Compositae) have been used in traditional Korean medicine as a cholagogic, antipyretic, anti-inflammatory, and diuretic purposes. In our previous study, ethanolic extracts of the plant demonstrated a marked anti-inflammatory effect in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells (J. Korean Soc. Appl. Biol. Chem., 2010, 53, 275-282).
METHODS AND RESULTS:
In the present study, Capillarisin (CPS), a flavone, main constituent of A. capillaris, was examined for its anti-inflammatory activity in the cells. We found that Capillarisin highly suppressed LPS-induced nitric oxide (NO) without exerting cytotoxic effects on RAW 264.7 cells. Capillarisin inhibited the expression of LPS-induced inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein and their mRNA in a dose-dependent manner. Also, tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and prostaglandin E(2) (PGE(2)) secretion were decreased by Capillarisin in LPS-stimulated macrophages. As a result, Capillarisin inhibited proinflammatory cytokines, iNOS, and COX-2, which is attributed to the suppression of LPS-induced ERK, JNK, and nuclear factor-κB (NF-κB) activation.
CONCLUSIONS:
Therefore, we demonstrate here that Capillarisin potentially inhibits the biomarkers related to inflammation through the abrogation of ERK, JNK, and NF-κB p65 activation, and it may be a potential therapeutic candidate for the treatment of inflammatory diseases.
Life Sci . 2020 Oct 15;259:118279.
Capillarisin protects SH-SY5Y cells against bupivacaine-induced apoptosis via ROS-mediated PI3K/PKB pathway[Pubmed: 32798562]
Abstract Aims: Bupivacaine, a common local anesthetic, can induce neurotoxicity and neurological complications. Capillarisin, a bioactive ingredient of Artemisia capillaris root extracts, has been reported to protect SH-SY5Y cells against oxidative stress-mediated neuronal cell death. Nevertheless, the effects of Capillarisin on bupivacaine-induced neurotoxicity in SH-SY5Y cells remain unclear. Main methods: Cell viability, lactate dehydrogenase (LDH) release, reactive oxygen species (ROS) production, and apoptosis were detected. Malondialdehyde (MDA) content, glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase (CAT) activities were measured for evaluation of oxidative stress. Western blot was performed to detect the changes of phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB) pathway, and expression of cleaved poly ADP ribose polymerase (PARP), cleaved caspase-3, glucose-regulated protein 78 (GRP78) and C/EBP homologous protein (CHOP). Activities of mitochondrial respiratory chain complexes I-III and adenosine triphosphate (ATP) content were measured to evaluate mitochondrial damage. Key findings: Bupivacaine treatment dose-dependently reduced cell viability, increased LDH release, and induced ROS production and PI3K/PKB pathway inactivation in SH-SY5Y cells, which were overturned by Capillarisin treatment. Capillarisin inhibited bupivacaine-induced apoptosis in SH-SY5Y cells by decreasing cleaved PARP and cleaved caspase-3 expression. Capillarisin inhibited bupivacaine-induced oxidative stress, decrease of mitochondrial respiratory chain complex I, II, and III activities and ATP content, and increase of GRP78 and CHOP expression in SH-SY5Y cells. However, treatment with LY294002 abolished the effects of Capillarisin on bupivacaine-induced neurotoxicity in SH-SY5Y cells. Significance: Capillarisin protected SH-SY5Y cells against bupivacaine-induced apoptosis by inhibiting oxidative stress, mitochondrial injury, and endoplasmic reticulum stress via ROS-mediated of PI3K/PKB pathway. Keywords: Bupivacaine; Capillarisin; Neurotoxicity; PI3K/PKB pathway; Reactive oxygen species.
In vivo:
J Ethnopharmacol. 2014 Mar 28;152(3):478-86.
Anti-hyperalgesic and anti-allodynic activities of capillarisin via suppression of inflammatory signaling in animal model.[Pubmed: 24495472]
Artemisia capillaris has widespread traditional and pharmacological applications such as analgesic, anti-inflammatory, anti-pyretic, enhance immunity and anti-tumor activity properties. To evaluate the pharmacological activities of this plant, Capillarisin, one of the potent constituent of Artemisia capillaris was studied based on anti-hyperalgesic and anti-allodynic effects with detailed mechanism. It can be assumed that measurement of anti-nociceptive effects of Capillarisin is one of the parameter for the evaluation of this herb. Capillarisin has extensive pharmacological properties and has been considered to have promising ant-inflammatory and anti-nociceptive activities. The aim of the current study is to investigate the effect of Capillarisin and underlying molecular mechanisms of action in preventing acute and subchronic inflammatory pain.
METHODS AND RESULTS:
The inflammatory pain was induced after 40 min or 1h of administration of vehicle, 70% EtOH extract of Artemisia capillaris (100mg/kg) or Capillarisin (20 and 80 mg/kg) by intraplantar (i.p.l.) injections of CFA and carrageenan in ICR mice, respectively. Mechanical hyperalgesia and allodynia were evaluated in both acute and subchronic models. Further analysis was performed in CFA-induced mice exploring various molecular and signaling pathways such as NF-κB, AP-1, and ERK-CREB involved in the persistent pain sensations. In acute model, mechanical hyperalgesia and allodynia were evaluated after every 2h until 6h of CFA and after 4h of carrageenan injections. Whereas, in subchronic inflammatory pain model, mechanical hyperalgesia and paw edema were measured after 4h of CFA injection and every day after 4h of daily treatment until 5 days with interval of day four in order to assess the tolerance effect of Capillarisin. Further analysis was performed in CFA-induced mice exploring various molecular and signaling pathways such as NF-κB, AP-1 and ERK-CREB involved in the persistent of pain sensations. Pre-treatment of Capillarisin strongly inhibited NF-κB mediated genes (iNOS, COX-2), involved in pain. The plasma leading nitrite production was significantly reduced by Capillarisin. Moreover, i.p. administration of Capillarisin markedly suppressed the adenosine 5׳-triphosphate (ATP) in plasma and substance P in CFA-induced paw tissue.
CONCLUSIONS:
The present study indicates that Capillarisin possessed promising anti-hyperalgesic and anti-allodynic effects through the inhibition of various inflammatory pain signaling, suggesting that Capillarisin constitutes a significant component for the treatment of inflammatory pain.
Capillarisin Description
Source: The herbs of Artemisia capillaris Thunb.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
Odontoside

Catalog No: CFN95530
CAS No: 20300-50-9
Price: $318/5mg
Dipsacussaponin C

Catalog No: CFN95353
CAS No: 152406-43-4
Price: $318/5mg
Melitidin

Catalog No: CFN95419
CAS No: 1162664-58-5
Price: $318/10mg
Malabaricone C

Catalog No: CFN95475
CAS No: 63335-25-1
Price: $318/10mg
5-Demethylsinensetin

Catalog No: CFN95415
CAS No: 21763-80-4
Price: $318/10mg
Vaccarin E

Catalog No: CFN95252
CAS No: 2252345-81-4
Price: $318/10mg
3'-Methoxymirificin

Catalog No: CFN95112
CAS No: 1297609-29-0
Price: $318/5mg
2-Methoxyfuranoguaia-9-ene-8-one

Catalog No: CFN95220
CAS No: 88010-62-2
Price: $318/10mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.162 mL 15.8098 mL 31.6196 mL 63.2391 mL 79.0489 mL
5 mM 0.6324 mL 3.162 mL 6.3239 mL 12.6478 mL 15.8098 mL
10 mM 0.3162 mL 1.581 mL 3.162 mL 6.3239 mL 7.9049 mL
50 mM 0.0632 mL 0.3162 mL 0.6324 mL 1.2648 mL 1.581 mL
100 mM 0.0316 mL 0.1581 mL 0.3162 mL 0.6324 mL 0.7905 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Protocol
Kinase Assay:
Cancer Lett. 2014 Apr 1;345(1):140-8.
Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases.[Pubmed: 24333736]
Signal transducers and activators of transcription (STAT)-3 is a latent cytosolic transcription factor that has been closely associated with survival, proliferation, chemoresistance, and metastasis of tumor cells. Whether the anti-proliferative, pro-apoptotic, and anti-metastatic effects of Capillarisin (CPS), derived from Artemisia capillaris (Compositae), are linked to its capability to inhibit STAT3 activation was investigated.
METHODS AND RESULTS:
We found that Capillarisin specifically inhibited both constitutive and inducible STAT3 activation at tyrosine residue 705 but not at serine residue 727 in human multiple myeloma cells. Besides the inhibition of STAT3 phosphorylation, Capillarisin also abrogated STAT3 constitutive activity and nuclear translocation. The suppression of STAT3 was mediated through the inhibition of activation of upstream JAK1, JAK2, and c-Src kinases. Treatment with the protein tyrosine phosphatase (PTP) inhibitor pervanadate treatment reversed the Capillarisin-induced down-regulation of JAK1/2 and STAT3, thereby suggesting the involvement of a PTP. Indeed, knockdown of the SHP-1 and SHP-2 genes by small interfering RNA suppressed the ability of Capillarisin to inhibit JAK1 and STAT3 activation, suggesting the critical role of both SHP-1 and SHP-2 in its possible mechanism of action. Capillarisin downregulated the expression of STAT3-regulated antiapoptotic and proliferative gene products; and this correlated with suppression of cell viability, the accumulation of cells in sub-G1 phase of cell cycle and induction of apoptosis. Moreover, Capillarisin potentiated bortezomib-induced apoptotic effects in MM cells, and this correlated with down-regulation of various gene products that mediate cell proliferation (Cyclin D1 and COX-2), cell survival (Bcl-2, Bcl-xl, IAP1, IAP2, and Survivin), invasion (MMP-9), and angiogenesis (VEGF).
CONCLUSIONS:
Thus, overall, our results suggest that Capillarisin is a novel blocker of STAT3 activation and thus may have a potential in negative regulation of growth, metastasis, and chemoresistance of tumor cells.
Cell Research:
Drug Res (Stuttg). 2014 Nov 4.
Capillarisin Exhibits Anticancer Effects by Inducing Apoptosis, Cell Cycle Arrest and Mitochondrial Membrane Potential Loss in Osteosarcoma Cancer Cells (HOS).[Pubmed: 25368903]
The aim of the present study was to assess the anticancer activity of Capillarisin against human osteosarcoma (HOS) cancer cells in vitro.
METHODS AND RESULTS:
Cell viability after Capillarisin drug treatment and evaluated by MTT assay. The extent of cell death induced by Capillarisin was estimated by using lactate dehydrogenase (LDH) assay. The effect of Capillarisin on cell cycle phase distribution and mitochondrial membrane potential (ΛΨm) was demonstrated via flow cytometry using propidium iodide (PI) and rhodamine-123 (Rh-123) DNA-binding fluorescent dyes respectively. Fluorescence microscopy was employed to examine the morphological changes in osteosarcoma cancer cells and presence of apoptotic bodies following Capillarisin treatment. The results of this study revealed that Capillarisin induced dose-dependent growth inhibition of these cancer cells after 12-h of incubation. Further, Capillarisin induced significant release of LDH from these cell cultures and this LDH release was much more noticeable at higher concentrations of Capillarisin. Hoechst 33258 staining revealed characteristic morphological features of apoptosis triggered by Capillarisin treatment. Cell cycle analysis revealed that Capillarisin induced dose-dependent G0/G1-phase cell cycle arrest. Capillarisin also trigerred a progressive and dose-dependent reduction in the mitochondrial membrane potential.
CONCLUSIONS:
In conclusion, Capillarisin inhibits cancer cell growth of osteosarcoma cells by inducing apoptosis accompanied with G0/G1-phase cell cycle arrest and loss in mitochondrial membrane potential.
Robinin

Catalog No: CFN98375
CAS No: 301-19-9
Price: $318/5mg
Daidzein

Catalog No: CFN98774
CAS No: 486-66-8
Price: $30/20mg
Oroxylin A

Catalog No: CFN98540
CAS No: 480-11-5
Price: $80/20mg
Isorhamnetin-3-O-beta-D-Glucoside

Catalog No: CFN99757
CAS No: 5041-82-7
Price: $218/10mg
Soyasapogenol D

Catalog No: CFN91069
CAS No: 65892-76-4
Price: $463/5mg
trans-4-Hydroxycinnamic acid

Catalog No: CFN98794
CAS No: 501-98-4
Price: $30/20mg
Ganoderic acid H

Catalog No: CFN92056
CAS No: 98665-19-1
Price: $318/10mg
Cyclo(Tyr-Pro)

Catalog No: CFN90276
CAS No: 5654-84-2
Price: $238/10mg
Calenduloside E

Catalog No: CFN91169
CAS No: 26020-14-4
Price: $268/10mg
Lonicerin

Catalog No: CFN95055
CAS No: 25694-72-8
Price: $168/10mg
Tags: buy Capillarisin | Capillarisin supplier | purchase Capillarisin | Capillarisin cost | Capillarisin manufacturer | order Capillarisin | Capillarisin distributor